2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-149069
    TSC25 98%
    TSC25 is a potent cruzipain (CZP) inhibitor, with an IC50 of 3.34 nM and a pIC50 of 8.48.
    TSC25
  • HY-149073
    TSC26 98%
    TSC26, a thiosemicarbazone, is a potent cruzipain (CZP) inhibitor with an IC50 of 175 nM, a pIC50 of 6.76 and a pKa of 6.6. TSC26 has the potential for parasitic diseases research.
    TSC26
  • HY-149078
    Antiparasitic agent-14 3046451-98-0 98%
    Antiparasitic agent-14 is a potent antiparasitic agent. Antiparasitic agent-14 shows cytotoxicity and antiparasitic activity. Antiparasitic agent-14 inhibits the growth of trypomastigote and amastigote.
    Antiparasitic agent-14
  • HY-149079
    Antiparasitic agent-15 3046451-91-3 98%
    Antiparasitic agent-15, a pyridine-thiazolidinone, has anti-Trypanosoma cruzi and leishmanicidal activities. Antiparasitic agent-15 has IC50s of 0.9 μM and 0.64 μM against trypomastigote and amastigote forms of T. cruzi. Antiparasitic agent-15 has IC50s of 42.2 μM and 9.58 μM against trypomastigote and amastigote forms of L. amazonensis. Antiparasitic agent-15 induces parasite cell death through necrosis induction. Antiparasitic agent-15 induces morphological changes such as shortening, retraction and curvature of the parasite body and leakage of internal content with T. cruzi trypomastigotes.
    Antiparasitic agent-15
  • HY-149080
    Antiparasitic agent-16 3046451-89-9 98%
    Antiparasitic agent-16, a pyridine-thiazolidinone, has anti-Trypanosoma cruzi and leishmanicidal activities. Antiparasitic agent-16 has IC50s of 1.0 μM and 0.6 μM against trypomastigote and amastigote forms of T. cruzi. Antiparasitic agent-16 has IC50s of 150.2 μM and 16.75 μM against trypomastigote and amastigote forms of L. amazonensis. Antiparasitic agent-16 induces parasite cell death through necrosis induction. Antiparasitic agent-16 induces morphological changes such as shortening, retraction and curvature of the parasite body and leakage of internal content with T. cruzi trypomastigotes.
    Antiparasitic agent-16
  • HY-149088
    Neuraminidase-IN-16 3049424-11-2 98%
    Neuraminidase-IN-16 (Compound 43b) is a potent neuraminidase inhibitor with IC50s of 0.031, 0.15, 0.25, 0.60, 0.63 and 10.08 μM against neuraminidase of H5N1, H5N8, H1N1, H3N2, H5N1-H274Y and H1N1-H274Y, respectively.
    Neuraminidase-IN-16
  • HY-149089
    Antibacterial agent 138 2971788-27-7 98%
    Antibacterial agent 138 has excellent antibacterial activity to multi-drug resistant bacteria. Antibacterial agent 138 inhibits bacterial protein synthesis but bacterial cell walls.
    Antibacterial agent 138
  • HY-149093
    Antileishmanial agent-14 1638956-72-5 98%
    Antileishmanial agent-14 is a sulfuretin analog with potential activity against the parasite Leishmania donovani promastigotes (IC50=4.1 μM). Antileishmanial agent-14 also inhibits infection by L. donovani amastigotes (IC50=11.1 μM).
    Antileishmanial agent-14
  • HY-149095
    Antibacterial agent 139 98%
    Antibacterial agent 139 has antibacterial activity against Gram-positive bacteria. Antibacterial agent 139 has anti-MRSA, anti-VISA, and anti-LRSE activities. Antibacterial agent 139 depolarizes the bacterial cell membrane.
    Antibacterial agent 139
  • HY-149125
    Globotriaosylceramide (porcine RBC) 71965-57-6 98%
    Globotriaosylceramide porcine RBC is a trihexosylceramide (Gb3) in porcine erythrocytes. Globotriaosylceramide porcine RBC is a natural resistance factor against HIV-1 infection. The synthetase α-galactosyltransferase (A4GALT) of Globotriaosylceramide porcine RBC is associated with HIV-1 resistance.
    Globotriaosylceramide (porcine RBC)
  • HY-149151
    Variegatic acid 20988-30-1 98%
    Variegatic acid is a secondary metabolite derived from basidiomycete fungi. Variegatic acid is a PKCβ1 inhibitor with an IC₅₀ of 36.2 μM. Variegatic acid inhibits antigen- or calcium ionophore-induced β-hexosaminidase release (IC₅₀ values of 10.4 μM and 22.2 μM, respectively) and TNF-α secretion (IC₅₀ values of 16.8 μM and 20.1 μM, respectively). Variegatic acid suppresses the enzymatic activity of calcium-activated PKCβ1 and reduces Fe(III) to Fe(II) in a pH-dependent manner, enabling the generation of hydroxyl radicals (·OH) through reaction with H₂O₂, which facilitates the degradation of lignocellulose. Variegatic acid is useful for studying biological degradation and allergic responses.
    Variegatic acid
  • HY-149154
    (4S,5S,6S,12aS)-Oxytetracycline 423769-22-6 98%
    (4S,5S,6S,12aS)-Oxytetracycline is a broad-spectrum antibiotic that can inhibit the synthesis of protein in bacteria. (4S,5S,6S,12aS)-Oxytetracycline is an important member of the bacterial aromatic polyketone family, a type of natural product with diverse structures.
    (4S,5S,6S,12aS)-Oxytetracycline
  • HY-149217
    Antiviral agent 27 2270947-36-7 98%
    Antiviral agent 27 (Compound 12) has notable activity against the Ebola virus (EC50: 14 nM).
    Antiviral agent 27
  • HY-149223
    FtsZ-IN-5 98%
    FtsZ-IN-5 is a potent FtsZ inhibitor, to promote FtsZ polymerization and inhibit GTPase activity of FtsZ. Thus, FtsZ-IN-5 inhibits bacterial division to lead to death of bacterial cells. FtsZ-IN-5 shows bactericidal activity with no significant tendency to trigger bacterial resistance as well as rapid bactericidal properties. And FtsZ-IN-5 shows low hemolytic activity and cytotoxicity to mammalian cells.
    FtsZ-IN-5
  • HY-149224
    FtsZ-IN-6 98%
    FtsZ-IN-6 is a potent FtsZ inhibitor, to promote FtsZ polymerization and inhibit GTPase activity of FtsZ. Thus, FtsZ-IN-6 inhibits bacterial division to lead to death of bacterial cells. FtsZ-IN-6 shows bactericidal activity with no significant tendency to trigger bacterial resistance as well as rapid bactericidal properties. And FtsZ-IN-6 shows low hemolytic activity and cytotoxicity to mammalian cells.
    FtsZ-IN-6
  • HY-149225
    FtsZ-IN-7 98%
    FtsZ-IN-7 is a potent FtsZ inhibitor, to promote FtsZ polymerization and inhibit GTPase activity of FtsZ. Thus, FtsZ-IN-7 inhibits bacterial division to lead to death of bacterial cells. FtsZ-IN-7 shows bactericidal activity with no significant tendency to trigger bacterial resistance as well as rapid bactericidal properties. And FtsZ-IN-7 shows low hemolytic activity and cytotoxicity to mammalian cells.
    FtsZ-IN-7
  • HY-149226
    FtsZ-IN-8 98%
    FtsZ-IN-8 is a potent FtsZ inhibitor, to promote FtsZ polymerization and inhibit GTPase activity of FtsZ. Thus, FtsZ-IN-8 inhibits bacterial division to lead to death of bacterial cells. FtsZ-IN-8 shows bactericidal activity with no significant tendency to trigger bacterial resistance as well as rapid bactericidal properties. And FtsZ-IN-8 shows low hemolytic activity and cytotoxicity to mammalian cells.
    FtsZ-IN-8
  • HY-149251
    DENV-IN-10 3043724-36-0 98%
    DENV-IN-10 is a potent tetravalent dengue inhibitor, with EC50s of 1.36, 0.87, 0.94, and 0.95 μM against DENV-1-4 serotypes, respectively. DENV-IN-10 is a post-entry replication inhibitor that appears to be specific for cells of primate origin.
    DENV-IN-10
  • HY-149256
    PLpro/RBD-IN-1 1282451-83-5 98%
    PLpro/RBD-IN-1 (compound 5) is a dual SARS-CoV-2 PLpro and spike protein RBD inhibitor with IC50s of 7.197 μM and 8.673 μM, respectively.
    PLpro/RBD-IN-1
  • HY-149263
    HAA-09 1422051-33-9 98%
    HAA-09 is an orally active and potent anti-influenza agent, targeting the influenza PB2_cap binding domain. HAA-09 displays potent anti-influenza A virus activity, with an EC50 of 0.03 μM. HAA-09 shows polymerase inhibition, with an IC50 of 0.06±0.004 μM. HAA-09 blocks virus replication without causing obvious cytotoxicity.
    HAA-09
Cat. No. Product Name / Synonyms Application Reactivity